Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Merrimack Pharma (MACK) to Divest Assets in Deal Valued at $1.03B
January 9, 2017 6:20 AM ESTMerrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen for a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack's exclusive licensing agreement with Shire, under which Merrimack will:
Sell to Ipsen its first commercial product ONIVYDE®, including U.S. commercialization rights and its licensing agreement with Shire plc; andSell to Ipsen its generic version of doxorubicin hydrochloride (HCI) liposome injection ("generic DOXIL®")... More
